|
| 37733830 | PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. | Clin Cancer Res | 2024 |
| 36115028 | Regional control after precision lymph node dissection for clinically evident melanoma metastasis. | J Surg Oncol | 2023 |
| 38040420 | Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. | J Immunother Cancer | 2023 |
| 35797609 | Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice. | Ann Surg | 2023 |
| 35588924 | Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysis. | J Am Acad Dermatol | 2023 |
| 37149545 | Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma. | Ann Surg Oncol | 2023 |
| 37384650 | Expression of microRNAs and their target genes in melanomas originating from gynecologic sites. | PLoS One | 2023 |
| 37072352 | Barriers to immune cell infiltration in tumors. | J Immunother Cancer | 2023 |
| 36746511 | Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine. | J Immunother Cancer | 2023 |
| 36646923 | Outcomes of Single Node Excision Compared with Lymph Node Dissection for Patients with Clinical Stage III N1b Cutaneous Melanoma. | Ann Surg Oncol | 2023 |
| 36538614 | A Step Toward Personalized Surgical Decision Making: Machine Learning Predicts 1 Versus Numerous Melanoma Lymph Node Metastases Using RNA-sequencing. | Ann Surg | 2023 |
| 36682343 | Evaluation of Preoperative and Intraoperative Mobile Gamma Camera Imaging in Sentinel Lymph Node Biopsy for Melanoma Independent of Preoperative Lymphoscintigraphy. | J Surg Res | 2023 |
| 36632563 | Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas. | Oncoimmunology | 2023 |
| 36202232 | Expression Patterns of microRNAs and Associated Target Genes in Ulcerated Primary Cutaneous Melanoma. | J Invest Dermatol | 2023 |
| 34480368 | A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer. | Int J Cancer | 2022 |
| 35803246 | Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. | Cell | 2022 |
| 35671681 | A Novel Fascial Flap Technique After Inguinal Complete Lymph Node Dissection for Melanoma. | J Surg Res | 2022 |
| 35537413 | An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. | Cancer Cell | 2022 |
| 36939214 | Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4<sup>+</sup> and CD8<sup>+</sup> T cells for immunotherapy of cancer. | J Immunother Cancer | 2022 |
| 35870116 | Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma. | J Surg Oncol | 2022 |
| 36176766 | A nano-enhanced vaccine for metastatic melanoma immunotherapy. | Cancer Drug Resist | 2022 |
| 35867209 | An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. | Ann Surg Oncol | 2022 |
| 36100309 | Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). | J Immunother Cancer | 2022 |
| 35896923 | ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. | Ann Surg Oncol | 2022 |
| 36169985 | CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab. | Melanoma Res | 2022 |
| 35921122 | Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. | JAMA Surg | 2022 |
| 35277457 | The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling. | J Immunother Cancer | 2022 |
| 34897715 | Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. | J Surg Oncol | 2022 |
| 32939793 | PRAME expression in 155 cases of metastatic melanoma. | J Cutan Pathol | 2021 |
| 33796406 | A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. | Oncoimmunology | 2021 |
| 33788957 | Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer. | J Surg Oncol | 2021 |
| 33619119 | Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8<sup>+</sup> T Cells. | Cancer Immunol Res | 2021 |
| 33704741 | Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures. | Methods Mol Biol | 2021 |
| 33704737 | Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes. | Methods Mol Biol | 2021 |
| 33890195 | Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. | Ann Surg Oncol | 2021 |
| 34454518 | Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163<sup>+</sup> myeloid cell infiltrates. | J Transl Med | 2021 |
| 34413169 | Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. | J Immunother Cancer | 2021 |
| 34413086 | Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. | Cancer Immunol Res | 2021 |
| 34103353 | Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. | J Immunother Cancer | 2021 |
| 34155069 | Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy. | J Immunol | 2021 |
| 34036233 | Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. | JCO Precis Oncol | 2021 |
| 34035112 | Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. | J Immunother Cancer | 2021 |
| 34289373 | Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. | Cell Rep | 2021 |
| 34167064 | Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. | Pathol Res Pract | 2021 |
| 34191790 | Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location. | J Immunother | 2021 |
| 33454795 | Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. | Cancer Immunol Immunother | 2021 |
| 33306984 | Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. | Cancer Cell | 2021 |
| 33208630 | IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. | Am J Surg Pathol | 2021 |
| 33479025 | Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). | J Immunother Cancer | 2021 |
| 32350119 | Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. | J Immunother Cancer | 2020 |